Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

MORU and SMRU were delighted and honoured to host the University of Oxford Vice-Chancellor Prof Louise Richardson and her party during her visit to Thailand on 1-4 September. Accompanying the Vice-Chancellor were Jeremy Woodall (Director of Development (Asia)), Frewyeni Kidane (Fundraiser for Southeast Asia), Cher Wu (Asia Development office) and Ed Gibbs (NDM Director of Finance and Operations).

Group photo of Vice-Chancellor Louise Richardson visiting MORU and SMRU

After landing in Bangkok on 1 Sept, the visitors flew to Mae Sot where they met with key staff from the SMRU programme. On 2 Sept, they visited the Wangpa Clinic, meeting with SMRU staff including midwives and local physicians, then went on to the SMRU offices in Mae Sod where they met office and laboratory researchers.

At the Faculty of Tropical Medicine on Tues 3r Sept, Vice-Chancellor Prof Richardson, Mr Woodall, Ms Kidane, Ms Wu and Mr Gibbs were welcomed by the Faculty Dean, Assoc Prof Pratap Singhasivanon. They then went on a tour of MORU departments and laboratories, meeting and chatting to many MORU and Faculty staff members. The visit was rounded off with a fantastic lunch hosted by the Dean and attended by many Faculty of Tropical Medicine Ajarns.

The following day Prof Richardson visited the Mahidol University campus at Salaya, meeting Prof Banchong Mahaisavariya, Acting President of Mahidol, and other senior Mahidol academics and discussing potential areas of collaboration between the two universities.”

- Text by Nick Day, with thanks to Rose McGready, Primprapaporn (Prim) Thongdee, Pawinee (Joy) Pawthong and David Burton for photos

Similar stories

Patient recruitment on track in Oxford-led DeTACT trial of safe, effective drug combinations to prevent the spread of artemisinin and multi-drug resistant malaria in Africa

Today is World Malaria Day. The global fight against malaria is at a critical point. No new antimalarial drugs are expected in the near future, and if multi-drug resistant falciparum malaria becomes established in East Africa and spreads to other parts of Africa, millions will be at risk of drug-resistant malaria infection and death. The development of triple artemisinin-based combination therapies aims to prevent or delay the emergence of artemisinin and multi-drug resistant malaria in Africa.

Under the Mask, drama film based on testimonies of tuberculosis patients

In 2022, tuberculosis (TB) remains a major global health problem, particularly in developing countries. On the Thai-Myanmar border, TB is an important problem among migrants, a vulnerable, very mobile population, with unstable, often difficult living conditions, insecure incomes, and poor access to health services.

TACT-CV study shows artemether–lumefantrine plus amodiaquine an effective treatment for multidrug-resistant malaria in GMS

A triple artemisinin-based combination therapy (TACT) of artemether-lumefantrine plus amodiaquine (AL+AQ) for uncomplicated falciparum malaria in areas with a high prevalence of artemisinin resistance is a well-tolerated, effective treatment for multidrug-resistant parasites, say a team of MORU-led researchers.

Largest-ever IPD meta-analysis of malaria patients to inform haemoglobin changes

A new malaria study using a very large analysis of pooled individual patient data (IPD) from more than 70,000 patients of all ages, has been published in BMC Medicine by the WorldWide Antimalarial Resistance Network Falciparum Haematology Study Group

Study finds steady increase in WHO-validated artemisinin resistance markers in Asia

From 2002-2018, there has been a steady increase in the places and proportion of infected people reporting validated kelch13 (K13) artemisinin resistance markers, according to a study in The Lancet Microbe. This increase in artemisinin resistance threatens efforts to eliminate malaria in Asia by 2030 — and control efforts in other endemic regions. The authors say that more consistent data collection, over longer time periods in the same areas, and rapid sharing of data are needed to map the spread of resistance and better inform policy decisions.

Global Research on AntiMicrobial resistance (GRAM) project

Antimicrobial resistance (AMR) is responsible for at least 1.27 million deaths per year — with over 97,000 deaths in 2019 in SE Asia alone, according to a study published in The Lancet by the Global Research on AntiMicrobial resistance (GRAM) project, who urged urgent action from policymakers and health communities to avoid further preventable deaths.